Correlation Between Edgewise Therapeutics and Lyell Immunopharma
Can any of the company-specific risk be diversified away by investing in both Edgewise Therapeutics and Lyell Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Edgewise Therapeutics and Lyell Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Edgewise Therapeutics and Lyell Immunopharma, you can compare the effects of market volatilities on Edgewise Therapeutics and Lyell Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Edgewise Therapeutics with a short position of Lyell Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Edgewise Therapeutics and Lyell Immunopharma.
Diversification Opportunities for Edgewise Therapeutics and Lyell Immunopharma
0.85 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Edgewise and Lyell is 0.85. Overlapping area represents the amount of risk that can be diversified away by holding Edgewise Therapeutics and Lyell Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyell Immunopharma and Edgewise Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Edgewise Therapeutics are associated (or correlated) with Lyell Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyell Immunopharma has no effect on the direction of Edgewise Therapeutics i.e., Edgewise Therapeutics and Lyell Immunopharma go up and down completely randomly.
Pair Corralation between Edgewise Therapeutics and Lyell Immunopharma
Given the investment horizon of 90 days Edgewise Therapeutics is expected to under-perform the Lyell Immunopharma. But the stock apears to be less risky and, when comparing its historical volatility, Edgewise Therapeutics is 1.14 times less risky than Lyell Immunopharma. The stock trades about -0.18 of its potential returns per unit of risk. The Lyell Immunopharma is currently generating about -0.07 of returns per unit of risk over similar time horizon. If you would invest 62.00 in Lyell Immunopharma on October 22, 2024 and sell it today you would lose (4.00) from holding Lyell Immunopharma or give up 6.45% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Edgewise Therapeutics vs. Lyell Immunopharma
Performance |
| Timeline |
| Edgewise Therapeutics |
| Lyell Immunopharma |
Edgewise Therapeutics and Lyell Immunopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Edgewise Therapeutics and Lyell Immunopharma
The main advantage of trading using opposite Edgewise Therapeutics and Lyell Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Edgewise Therapeutics position performs unexpectedly, Lyell Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will offset losses from the drop in Lyell Immunopharma's long position.| Edgewise Therapeutics vs. Century Therapeutics | Edgewise Therapeutics vs. C4 Therapeutics | Edgewise Therapeutics vs. Mineralys Therapeutics, Common | Edgewise Therapeutics vs. Cullinan Oncology LLC |
| Lyell Immunopharma vs. Cullinan Oncology LLC | Lyell Immunopharma vs. Monte Rosa Therapeutics | Lyell Immunopharma vs. Revolution Medicines | Lyell Immunopharma vs. Nkarta Inc |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Complementary Tools
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |